ACEI/ARB类降压药物在肿瘤治疗中的临床研究进展

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (2): 230-234.

ACEI/ARB类降压药物在肿瘤治疗中的临床研究进展

王增¹, 袁梅琴², 杨国浓¹, 丁海樱¹

¹浙江省肿瘤医院药剂科,杭州 310022,浙江;
²浙江省肿瘤医院化疗中心,杭州 310022,浙江

收稿日期:2014-06-21 修回日期:2014-12-11 出版日期:2015-02-26 发布日期:2015-03-20
通讯作者: 杨国浓,女,本科,主任药师,研究方向:医院药学。Tel: 0571-88122118 E-mail: ygn454@aliyun.com
作者简介:王增,女,硕士,主管药师,研究方向:肿瘤药理学,医院药学。Tel: 0571-88122438 E-mail: shulinsally@aliyun.com
基金资助:
浙江省药学会医院药学专项科研资助项目(2013ZYY06)

Clinical research progress of ACEI/ARB used in tumor treatment

WANG Zeng¹, YUAN Mei-qin², YANG Guo-nong¹, DING Hai-ying¹

¹Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China;
²Department of Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China

Received:2014-06-21 Revised:2014-12-11 Online:2015-02-26 Published:2015-03-20

摘要/Abstract

摘要： 血管紧张素转化酶抑制剂(ACEI)和血管紧张素受体Ⅱ抑制剂(ARB)类药物是临床心脑血管系统常用药物, 一些流行病学研究发现其具有抗肿瘤作用。有一些临床研究表明ACEI/ARB类药物在肿瘤合并高血压人群中表现出潜在的抗肿瘤作用。就其最新临床研究进展进行综述。

关键词: 血管紧张素转化酶抑制剂, 血管紧张素受体Ⅱ抑制剂, 肿瘤, 临床研究

Abstract: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are commonly used in clinical cardiovascular system diseases. Recently, some epidemiological studies found its potential antitumor effect. Several clinical studies showed that ACEI/ARB drugs exerted antitumor effect when used in hypertensive individuals with tumor. Thus, we summarized the latest clinical research progress as follows.

Key words: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, tumor, clinical trails

中图分类号:

王增, 袁梅琴, 杨国浓, 丁海樱. ACEI/ARB类降压药物在肿瘤治疗中的临床研究进展[J]. 中国临床药理学与治疗学, 2015, 20(2): 230-234.

WANG Zeng, YUAN Mei-qin, YANG Guo-nong, DING Hai-ying. Clinical research progress of ACEI/ARB used in tumor treatment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 230-234.

参考文献

[1] Zeng F, Harris RC. Epidermal growth factor, from gene organization to bedside [J]. Semin Cell Dev Biol, 2014, 28(5): 2-11.
[2] Evans T. Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC [J]. Anticancer Res, 2012, 32(11): 4629-4638.
[3] Huang CC, Chan WL, Chen YC, et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension [J]. Am J Cardio, 2011,107(7): 1028-1033.
[4] Sjo¨berg T, Garc＇a Rodr＇guez LA, Lindblad M. Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study [J]. Clin Gastroenterol Hepatol, 2007, 5(10): 1160-1166.
[5] Radulescu D, Buzdugan E, Ciuleanu TE, et al. Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors [J]? J BUON, 2013, 18(4): 1052-1057.
[6] Lever AF, Hole DJ, Gillis CR, et al . Do inhibitor so fangio-tensin-I-converting enzyme protect against risk of cancer [J]? Lancet, 1998, 352(9123) : 179-184.
[7] Ronquist G, Rodriguez LA, Ruigomez A , et al. Association between captopri, l other antihypertensive drugs and risk of prostate cancer [J]. Prostate, 2004, 58(1): 50-56.
[8] Meier CR, Derby LE, Jick SS, et al. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer [J]. Arch Intern Med, 2000, 160(3): 349-353.
[9] Pasternak B, Svanstro¨m H, Callre＇us T, et al. Use of angiotensin receptor blockers and the risk of cancer[J]. Circulation, 2011, 123(16): 1729-1736.
[10]Chang CH, Lin JW, Wu LC, et al. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study[J]. J Clin Oncol, 2011, 29(22): 3001-3007.
[11]Haiman CA, Henderson SO, Bretsky P, et al. Genetic variation in angiotensin I-converting enz yme ( ACE ) and breast cancer risk : the multiethnic cohort [J]. Cancer Res, 2003, 63(20): 6984.
[12]Friis S, Sørensen HT, Mellemkjær L, et al. Angiotensinconverting enzyme inhibitors and the risk of cancer: a populationbased cohort study in Denmark[J]. Cancer, 2001, 92(9): 2462-2470.
[13]Lindholm LH, Anderson H, Ekbom T, et al. Relation between drug treatment and cancer in hypertensives in the Swedish trial in old patients with hypertension 2: a 5-year, prospective, randomised, controlled trial[J]. Lancet, 2001, 358(9281): 344-539.
[14]Coleman CI, Baker WL, Kluger J, et al. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials[J]. J Hum Hypertens, 2008, 26(4): 622-629.
[15]Ganz PA, Habel LA, Weltzien EK, et al. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort[J]. Breast Cancer Res Treat, 2011, 129(2): 549-556.
[16]Stefan W, Sabine VH, Martina C, et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy[J]. J Cancer Res Clin Oncol, 2009, 135(10): 1429-1435.
[17]Chae YK, Brown EN, Lei X, et al. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes[J]. J Cancer, 2013, 4(7): 549-556.
[18]Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2011, 29(19): 2645-2652.
[19]Kim ST, Park KH, Oh SC, et al. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy[J]? Oncology, 2012, 83(6): 354-360.
[20]Engineer DR, Burney BO, Hayes TG, et al. Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer[J]. Transl Oncol, 2013, 6(5): 539-545.
[21]Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine[J]. Br J Cancer, 2010, 103(11): 1644-1648.
[22]Keizman D, Huang P, Eisenberger MA, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination[J]. Eur J Cancer, 2001, 47(13): 1955-1961.
[23]Buchler T, Krejci M, Svobodnik A, et al. Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy[J]. Hematol J, 2005, 5(7): 559-564.
[24]Yoshiji H, Noguchi R, Toyohara M, et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma[J]. J Hepatol, 2009, 51(2): 315-321.
[25]Chen YH, Huang CH, Lu HI, et al. Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma[J]. J Renin Angiotensin Aldosterone Syst, 2014 Jun 24. pii: 1470320314535275.
[26]Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth[J]. J Clin Invest, 2003, 112(1): 67-75.
[27]Rivat C, Rodrigues S, Bruyneel E, et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)- and vascular endothelial growth factor-mediated cellular invasion and tumor growth[J]. Cancer Res, 2005, 65(1): 195-202.
[28]Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy[J]. Carcinogenesis, 2008, 29(9): 1675-1684.